GlassScriptPhysician profile
James C Mosley
NPI 1518090125
$3,638.02
in general payments reported to CMS, 2019-2025
36 companies · $480 in 2025
The $480 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $64.18 · 2021: $1,492 · 2022: $161 · 2023: $525 · 2024: $473 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,432.13 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $704.39 | 2022-2025 | |
| Tempus Ai, INC | $187.50 | 2024 | Xt Cdx |
| Pfizer INC. | $145.87 | 2019-2024 | |
| Celgene Corporation | $143.77 | 2019-2020 | |
| Gilead Sciences, INC. | $98.39 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $88.55 | 2019-2022 | |
| Amgen INC. | $81.55 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $66.13 | 2019-2025 | Ninlaro |
| Astellas Pharma US INC | $59.61 | 2020-2025 | Cresemba, Xtandi |
| Daiichi Sankyo INC. | $57.43 | 2024-2025 | Injectafer, Enhertu, Vanflyta |
| Kite Pharma, INC. | $52.08 | 2024 | Yescarta |
| Genentech USA, INC. | $49.95 | 2019-2021 | |
| Abbvie INC. | $44.13 | 2025 | |
| Glaxosmithkline, LLC. | $42.25 | 2021-2023 | Ojjaara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $38.06 | 2025 | |
| Array Biopharma INC | $35.47 | 2022-2023 | Mektovi, Lorbrena, Braftovi |
| Springworks Therapeutics, INC. | $31.70 | 2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $30.98 | 2019-2025 | Pyrukynd |
| Exelixis INC. | $28.33 | 2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $27.21 | 2019-2022 | |
| Incyte Corporation | $23.05 | 2019 | |
| Beigene USA, INC. | $20.21 | 2023 | Brukinsa |
| Eisai INC. | $20.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.24 | 2023 | Monoferric |
| Alnylam Pharmaceuticals INC. | $14.90 | 2023 | Amvuttra |
| Lilly USA, LLC | $14.21 | 2019 | |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
| Myriad Genetic Laboratories, INC. | $13.80 | 2022 | |
| Foundation Medicine, INC. | $13.40 | 2021 | |
| Taiho Oncology, INC. | $12.04 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.